Psoriasis drugs dominated the TV pharma ad landscape in March, as Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi secured the top two spots in iSpot.tv’s ad rankings. The two drugs rose up the list ...
Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is ...
TREMFYA ® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children ...
For years, managing active psoriatic arthritis (PsA) has been a race against time, with irreversible joint damage and long-term disability often the heartbreaking end-point for patients. Now, a major ...
Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis. The FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback